Cregis Shines at Paris Blockchain Week 2026, Accelerating European Expansion Fate Therapeutics Highlights iPSC-derived, Off-the-shelf CAR NK Cell Programs for Multiple Myeloma at 2022 ASH Annual Meeting
Interim Phase 1 Data of FT576 BCMA-targeted Product Candidate Show Clinical Activity in Initial Single-dose…
Affimed Provides Updated Clinical Data from Phase 1/2 Study of AFM13 Precomplexed with Cord Blood-Derived NK Cells at the ASH 2022 Annual Meeting
AFM13 in combination with NK cells shows very high overall and complete response rates in…
Tessa Therapeutics Announces New Clinical Data from Phase 1 Allogeneic Study Presented at 2022 Annual Meeting of American Society of Hematology (ASH)
Oral podium presentation highlights data demonstrating a 79% overall response rate and complete responses in…
Janssen Presents First Data from MajesTEC-2 Trial of TECVAYLI®▼ (teclistamab) in Combination with DARZALEX® (daratumumab) Subcutaneous (SC) Formulation and Lenalidomide in Relapsed or Refractory Multiple Myeloma
Initial Phase 1b study results show clinical activity with immune-based triplet therapy regimen1 BEERSE, Belgium,…
New Results from the Phase 3 GLOW Study of Fixed-Duration Treatment with IMBRUVICA® (ibrutinib) Plus Venetoclax Demonstrate Robust Efficacy and Sustained Response in Older, Unfit Patients with Previously Untreated Chronic Lymphocytic Leukaemia
With nearly four years of study follow-up, all-oral, fixed-duration IMBRUVICA® (ibrutinib) + venetoclax reduced the…
Janssen Presents New Data for Talquetamab, a GPRC5DxCD3 Bispecific Antibody, Showing Durable Responses in Patients with Heavily Pretreated Multiple Myeloma
Results from the pivotal MonumenTAL-1 study, including first results from the Phase 2 portion, featured…
argenx to Present Pivotal ADVANCE Trial Data During ASH Plenary Session Highlighting VYVGART® (efgartigimod alfa-fcab) as Potential New Treatment Modality for Immune Thrombocytopenia
First immune thrombocytopenia (ITP) plenary selection in 15 years underscores significant unmet need in this…
Kura Oncology Presents Updated Clinical Data from KOMET-001 Trial of Menin Inhibitor Ziftomenib at American Society of Hematology Annual Meeting
– 30% CR rate at 600 mg in 20 patients with relapsed/refractory NPM1-mutant AML ––…
Sutro Biopharma Announces Presentation of STRO-002 Data from the Compassionate Use Program in Pediatric Patients with Relapsed/Refractory CBF/GLIS AML at ASH 2022
– A total of 17 pediatric patients were treated with STRO-002 on a compassionate use…
LAVA Therapeutics Announces Updated Data from the Phase 1/2a Clinical Trial of LAVA-051 at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition
Poster presentation to include initial data from subcutaneous administration and updates on intravenous dosing-cohorts UTRECHT,…
AltruBio Presents New Positive Data from its Completed Phase 1b Study Evaluating ALTB-168 in Patients with Steroid-Refractory or Treatment-Refractory Acute Graft-Versus-Host-Disease at the 64th ASH Annual Meeting 2022
-Participants with SR-aGVHD disease achieved an ORR of 67% and CR of 17% as measured…
Adaptive Biotechnologies Highlights New Data Showcasing the Clinical Utility of clonoSEQ® MRD Testing in Patients with Blood Cancers at the 64th ASH Annual Meeting
Multiple presentations reinforce clonoSEQ’s ability to provide valuable insights for treatment surveillance and clinical decision-making…
Fate Therapeutics Announces Clinical Safety and Activity Data of First-ever iPSC-derived CAR T-cell Therapy at 2022 ASH Annual Meeting
FT819 Off-the-Shelf CAR T-cell Product Candidate Derived from Clonal Engineered Master iPSC Line with Novel…
UREEQA partners i-Create to validate new NFT collection Joe Ravioli
ONTARIO, CA, Dec 10, 2022 – (ACN Newswire) – The founders of i-Create LLC are…
ScottHall.co Reveals Email List Building Best Practices for SMBs in New Guide
Digital marketing e-commerce consultancy ScottHall.co has released a Best Practices guide that offers entrepreneurs and…
The best of the best real estate developers, projects prevail at 17th PropertyGuru Asia Property Awards Grand Final
BANGKOK, THAILAND, Dec 10, 2022 – (ACN Newswire) – PropertyGuru Group (NYSE: PGRU), Southeast Asia’s…
Faraday Future to Host Virtual Global Investor Business Update on Thursday, December 15th, 2022
LOS ANGELES–(BUSINESS WIRE)–Faraday Future (“FF”), a California-based global shared intelligent electric mobility ecosystem company, announced…
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Singularity Future Technology Ltd. with Losses of $100,000 to Contact the Firm
LOS ANGELES–(BUSINESS WIRE)–$SGLY #SGLY—The Schall Law Firm, a national shareholder rights litigation firm, reminds investors…
Puerto Rico HTA Bankruptcy Exit Reduces Assured Guaranty’s Insured Puerto Rico Exposure by $711 Million; Assured Guaranty Continues to Protect Insured Bondholders
HAMILTON, Bermuda–(BUSINESS WIRE)–On December 6, 2022, the Modified Fifth Amended Title III Plan of Adjustment…
EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Singularity Future Technology Ltd. f/k/a Sino-Global Shipping America Ltd. – SGLY
NEW YORK–(BUSINESS WIRE)–Rosen Law Firm, a global investor rights law firm, announces it has filed…